Hansa Biopharma (Hansa) will host a virtual investor event on Guillain-Barré syndrome (GBS) on 16 June 2025. The webcast aims to highlight the company’s ongoing research efforts and pipeline developments targeting this rare neurological condition. The event will feature expert insights into the GBS treatment landscape. David Cornblath, professor emeritus of neurology at Johns Hopkins […]
The post Hansa Biopharma to host investor event on Guillain-Barré Syndrome to accelerate research appeared first on Pharmafile.
